On February 19, 2026, Envoy Medical announced that its pivotal clinical trial for the world's first fully implanted cochlear implant has reached 80% enrollment. Forty-five patients have now been successfully implanted with the Acclaim® device, a technology that eliminates every piece of external hardware from traditional cochlear implants.

This is an AMAZING moment because it solves one of the most persistent barriers to cochlear implant adoption: visibility. For decades, people with severe hearing loss have rejected life-changing implants because they require visible external microphones and processors worn behind the ear. Acclaim® changes that equation entirely. Everything is internal. Nothing is visible. The device uses the natural eardrum as a sensor, capturing sound through the body's own anatomy instead of through external hardware.

The implications are immediate and measurable. Traditional cochlear implants require users to remove external components before swimming, showering, or sleeping. Acclaim® users will have continuous 24/7 hearing access. The psychological impact is equally significant. Studies show that visible hearing technology carries social stigma, particularly among young adults and working professionals. An invisible implant removes that barrier.

The technology represents a fundamental reimagining of how cochlear implants work. Traditional devices capture sound through an external microphone, process it digitally, and transmit signals through the skin to an internal electrode array. Acclaim® eliminates the external microphone entirely. Instead, it attaches a sensor directly to the eardrum. When sound waves cause the eardrum to vibrate, the sensor converts those vibrations into electrical signals. The system then processes and delivers those signals to the cochlear electrode array. The natural ear anatomy becomes part of the device.

Envoy Medical expects to complete enrollment of all 56 patients by the end of March 2026. The company will then submit its data to the FDA for approval. If approved, Acclaim® will be the first fully implanted cochlear implant available in the United States. The company has already secured $78 million in financing to fund clinical trials, regulatory submission, and initial commercialization.

The market need is substantial. According to the World Health Organization, 466 million people worldwide have disabling hearing loss. Of those, approximately 70 million have severe to profound hearing loss that could benefit from cochlear implants. Current adoption rates remain low, partly due to the visibility and lifestyle restrictions of external hardware. An invisible, always-on solution could reach patients who have rejected traditional implants.

I am Henry P., and I believe this is genuine progress. The device is not a cure for hearing loss, but it is meaningful advancement. It eliminates barriers that have prevented people from accessing critical sound awareness for decades.

But I want to be honest with you. Acclaim® is still investigational. It has not yet received FDA approval. The device is only suitable for people with severe to profound hearing loss, not for mild or moderate cases. It requires surgery, just like traditional cochlear implants. Users will still need programming and adjustments. It will not restore normal hearing. It provides access to sound, speech understanding, and safety awareness, but expectations must remain realistic.

The clinical trial is measuring both safety and efficacy. Envoy Medical must demonstrate that the fully implanted system performs comparably to external-microphone systems while maintaining patient safety. Success rates and hearing outcome data will not be available until the trial completes and results are analyzed. The FDA will evaluate that data before making approval decisions.

Cochlear implant technology has been advancing for 60 years. The first single-channel implant was approved in 1984. Multi-channel devices came in the 1990s. Processing algorithms improved through the 2000s and 2010s. Each generation made sound quality better, but the fundamental architecture remained unchanged: external microphone, external processor, internal receiver. Acclaim® breaks that pattern.

If approved, the device will not replace traditional cochlear implants. External-microphone systems will remain the standard for children, for people who cannot tolerate additional surgery, and for those who prefer tried-and-tested technology. Acclaim® will expand options. It will reach adults with severe hearing loss who want invisibility and continuous hearing access.

The first Acclaim® patients could receive FDA-approved devices in late 2026 or early 2027, pending successful trial completion and regulatory review. For the first time, cochlear implant candidates will have a choice: visible but proven technology, or invisible but newer technology. That choice represents progress.

Sources: